PIK3CB and cancer: A combinatorial drug screen preclinical study has recently identified that CDK 4/6 inhibition sensitizes cells with acquired and intrinsic resistance to PI3K inhibition on multiple PIK3CA mutant cancers with decreased sensitivity to PI3K inhibitors.